title: Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
authors.forename: Theodore
authors.initials: T
authors.lastname: Liakakos
authors.forename: Dimitrios H
authors.initials: DH
authors.lastname: Roukos
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D004195:Disease Models, Animal; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D051379:Mice; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D011758:Pyrroles / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib; D020123:Sirolimus